首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1423608篇
  免费   113912篇
  国内免费   3389篇
耳鼻咽喉   18471篇
儿科学   46896篇
妇产科学   41369篇
基础医学   202384篇
口腔科学   37902篇
临床医学   126791篇
内科学   287487篇
皮肤病学   33748篇
神经病学   117799篇
特种医学   54044篇
外国民族医学   464篇
外科学   212264篇
综合类   32867篇
现状与发展   3篇
一般理论   489篇
预防医学   111325篇
眼科学   31810篇
药学   99293篇
  1篇
中国医学   3382篇
肿瘤学   82120篇
  2021年   11184篇
  2019年   11984篇
  2018年   16889篇
  2017年   12908篇
  2016年   14486篇
  2015年   16283篇
  2014年   22932篇
  2013年   33911篇
  2012年   46131篇
  2011年   48700篇
  2010年   28595篇
  2009年   27476篇
  2008年   44999篇
  2007年   47547篇
  2006年   48090篇
  2005年   46557篇
  2004年   44341篇
  2003年   42326篇
  2002年   40729篇
  2001年   73278篇
  2000年   74836篇
  1999年   61865篇
  1998年   17113篇
  1997年   15532篇
  1996年   15671篇
  1995年   14869篇
  1994年   13482篇
  1993年   12636篇
  1992年   46000篇
  1991年   43640篇
  1990年   41629篇
  1989年   39686篇
  1988年   36303篇
  1987年   35459篇
  1986年   32966篇
  1985年   31377篇
  1984年   23895篇
  1983年   20094篇
  1982年   12236篇
  1981年   10804篇
  1979年   20747篇
  1978年   14612篇
  1977年   12123篇
  1976年   11398篇
  1975年   11662篇
  1974年   14033篇
  1973年   13584篇
  1972年   12682篇
  1971年   11501篇
  1970年   10946篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
62.
63.

Background

The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.

Methods

Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.

Results

Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.

Conclusions

No safety concerns arose, supporting the favorable benefit-risk profile of RZV.  相似文献   
64.
BACKGROUND. The identification and treatment of individuals with tuberculosis (TB) is a global public health priority. Accurate diagnosis of pulmonary active TB (ATB) disease remains challenging and relies on extensive medical evaluation and detection of Mycobacterium tuberculosis (Mtb) in the patient’s sputum. Further, the response to treatment is monitored by sputum culture conversion, which takes several weeks for results. Here, we sought to identify blood-based host biomarkers associated with ATB and hypothesized that immune activation markers on Mtb-specific CD4+ T cells would be associated with Mtb load in vivo and could thus provide a gauge of Mtb infection.METHODS. Using polychromatic flow cytometry, we evaluated the expression of immune activation markers on Mtb-specific CD4+ T cells from individuals with asymptomatic latent Mtb infection (LTBI) and ATB as well as from ATB patients undergoing anti-TB treatment.RESULTS. Frequencies of Mtb-specific IFN-γ+CD4+ T cells that expressed immune activation markers CD38 and HLA-DR as well as intracellular proliferation marker Ki-67 were substantially higher in subjects with ATB compared with those with LTBI. These markers accurately classified ATB and LTBI status, with cutoff values of 18%, 60%, and 5% for CD38+IFN-γ+, HLA-DR+IFN-γ+, and Ki-67+IFN-γ+, respectively, with 100% specificity and greater than 96% sensitivity. These markers also distinguished individuals with untreated ATB from those who had successfully completed anti-TB treatment and correlated with decreasing mycobacterial loads during treatment.CONCLUSION. We have identified host blood-based biomarkers on Mtb-specific CD4+ T cells that discriminate between ATB and LTBI and provide a set of tools for monitoring treatment response and cure.TRIAL REGISTRATION. Registration is not required for observational studies.FUNDING. This study was funded by Emory University, the NIH, and the Yerkes National Primate Center.  相似文献   
65.
66.
67.
68.
69.
70.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号